AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community

Galderma (SWX:GALD) will showcase a strong presence at the 23 ^rd Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco from March 27-29, 2025, with two symposia, four Masterclass sessions, 11 research e-posters, and an experiential Galderma lounge alongside its interactive booth (O2, Hall Ravel) featuring five Meet-the-Expert sessions.

This extensive program highlights the breadth of Galderma’s leading Injectable Aesthetics portfolio, designed to address the present and future needs of patients and healthcare professionals alike.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319676050/en/

Expert perspectives on the hottest topics in injectable aesthetics today

Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with alterations in facial aesthetic appearance of variable magnitude. ¹⁴ In the largest study investigating facial changes in medication-driven weight loss to date, Galderma surveyed more than 1,300 people across five countries. ¹³ Findings from this first-of-its kind study will be presented, showing 93% of those undergoing weight loss treatment noticed some degree of facial changes during their treatment and many patients are considering aesthetic treatments to address these, with biostimulators and dermal fillers being the most frequently considered treatments. ¹³ The Galderma-sponsored “Medication-Driven Weight Loss: The Algorithms" symposium taking place on Thursday, March 27, as well as a dedicated Masterclass session on Friday, March 28, will explore the effects medication-driven weight loss can have on the face and dive into the ways aesthetic procedures can help restore facial volume and structure. The symposium will feature live demonstrations and expert insights from Dr. Luiz Avelar, Dr. Priyanka Chadha, Prof. Sebastian Cotofana, Dr. Sabrina Fabi, Dr. Marcus Morais, and Dr. Andreas Nikolis.

Galderma will also host the "GAIN Experts Dialogue: Defining the Ideal Lips" symposium on Thursday, March 27, featuring expert speakers Prof. Sebastian Cotofana, Dr. Simone Doreian, Dr. Stephanie Lam, Dr. Christoph Martschin, and Dr. Andrei Metelitsa. This session, through insightful debates, cultural and anatomical discussions, and live injection demonstrations, will explore the evolving techniques in aesthetic lip treatments as well as patient standards and preferences for natural looking and feeling results. A Masterclass session will also be held to dive deeper into these techniques on Saturday, March 29.

New data cements the unique ability of Galderma’s products to meet patient needs

Galderma will present new data from the phase IIIb EXPRESSION and RELAX studies, showing Relfydess achieved rapid onset of action and significant aesthetic improvement in frown lines and crow’s feet. ^1,2 In the EXPRESSION study more than 50% of patients reported visible effects as early as day one and, in the RELAX study, effects were sustained through six months, confirming results seen in the READY trial program and more than a third saw improvement beyond six months in frown lines. ^1,2 Both studies re-confirmed high patient satisfaction with Relfydess, with 70% of patients in the RELAX study reporting that they preferred treatment with Relfydess versus prior treatments received. ^1,2 Encore data from a post-hoc analysis of the phase III READY program will show that, regardless of baseline wrinkle severity (moderate/severe), subjects treated with Relfydess achieved high rates of improvement in frown lines and crow’s feet, along with improved well-being, and a sustained effect through six months. ¹⁵

Galderma will also present new data on Sculptra (PLLA-SCA), the first proven regenerative biostimulator, reinforcing its unique formulation, efficacy, and safety. ^3-12 New in vivo comparative data will demonstrate its favorable tissue response and slower, controlled product degradation profile at 52 weeks, as well as lower inflammation, compared to PLLA-GA. ¹¹ The lower inflammation is consistent with Sculptra's well-established safety profile. ³ Differences in formulation can significantly impact local tissue response and product degradation, affecting potential clinical outcomes such as efficacy and duration. ¹¹ An expert consensus also confirms Sculptra’s key role in the regenerative aesthetic field and additional data will show its synergistic effect when paired with Alastin ^® , underscoring its effect across all three skin layers. ^12,16

Encore data to be presented on Restylane Shaype™, powered by Galderma’s proprietary NASHA HD™ Technology and approved in Canada and most recently in Brazil, will show that it constitutes a breakthrough innovation in hyaluronic acid fillers as the firmest hyaluronic acid injectable available and displaying the highest G-prime (indicating superior gel strength and firmness) on the market providing a unique bone mimicking effect. ^17,18 Additional pooled and pivotal phase IV data to be presented will show that Restylane fillers preserve or enhance the natural expressions of 98% of patients while achieving desired aesthetic improvements in attractiveness and youthfulness. ¹⁹ This naturalness, combined with high patient satisfaction, represents long-lasting aesthetic improvement. ¹⁹ To date, Restylane is the first and only hyaluronic acid filler to have in vivo data demonstrating its efficacy in restoring and maintaining the naturalness of expression. ^19-22

These e-posters, along with others presented on Dysport ^® and Alastin, will reinforce Galderma’s strong dedication to equipping practitioners with the products they need to achieve natural, long-lasting results for their patients.

More details on Galderma’s scientific presentations at AMWC can be found here . Media can watch this video to find out more about facial changes associated with medication-driven weight loss and this video to learn more about the natural looking results of Restylane products.

About Relfydess (RelabotulinumtoxinA)

Pioneered by Galderma, Relfydess is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology that is designed to preserve molecule integrity. ²³ PEARL Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months. ^24-27 Relfydess is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time. ^23,28 It was entirely created and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. Relfydess received a marketing authorization in several markets. RelabotulinumtoxinA is an investigational drug product in the U.S. Authorization conditions may vary internationally.

About the Restylane Portfolio

Restylane hyaluronic acid (HA) injectables are Designed Differently to go beyond volumizing for natural-looking results. ^29-32 Our HA is exceptionally pure, making it the closest to the skin’s own. ³³ Our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose. Restylane unique technologies, NASHA HD ^™ , NASHA ^® and OBT™ are meaningfully designed to mimic the diverse range of facial structures and skin layers. ^29-31 With the Highest G’ and Highest flexibility, Restylane can provide from structural support to natural expression to a healthy glow. ^17,30,33-36 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural looking results. ^22,29,37

About Sculptra

Sculptra is the first proven regenerative biostimulator, with a unique PLLA-SCA™ formulation that helps restore the deep, underlying structure of the skin by inducing a foreign body reaction. ^{3,48-10,38-47} Sculptra works to address the underlying causes of facial aging, including degradation of the extracellular matrix, which results in volume loss, laxity, and the appearance of wrinkles. ^3,41,45-47 Sculptra encourages the remodeling of components of the extracellular matrix, such as elastin and collagen, helping to gradually restore facial volume and the look of fullness to wrinkles and folds over time. ^48-51 The results from Sculptra are long-lasting, with optimal correction seen in approximately three months and results lasting up to two years. ^4,46,7,52

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com .

References

1. Shridharani S, Coquis-knezek S and Prygova I. Aesthetic improvement and rapid results in glabellar and lateral canthal lines after treatment with the innovative liquid relabotulinumtoxinA formulation. Presented at AMWC 2025; Mar 27-29, 2025; Monaco
2. Ablon G, et al. Subject preference and satisfaction with liquid relabotulinumtoxinA treatment of glabellar lines over 12 months, in a randomized controlled trial. Presented at AMWC 2025; Mar 27-29, 2025; Monaco
3. Galderma. Sculptra EU Instructions For Use 2023
4. Widgegrowl J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds). IMCAS Poster 2024. Paris, France
5. Galderma. Data on file. MA-50526. 43USSA1812 clinical study report. Fort Worth, TX: Galderma Laboratories, L.P. 2022
6. Bohnert K, et al. Randomized, Controlled, Multicentered, Double-Blind Investigation of Injectable Poly-L-Lactic Acid for Improving Skin Quality. Dermatol Surg 2019;45:718–724
7. Hexsel D, et al. Introducing the L-Lift—A Novel Approach to Treat Age-Related Facial Skin Ptosis Using A Collagen Stimulator. Dermatol Surg: Letters & Communications. 2019
8. Galderma. Data on File (MA-60875)
9. Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042
10. Huth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791
11. Avelar L, et al. Comparing two biostimulators on the local tissue response and degradation up to 52 weeks in vivo with an indirect comparison to clinical outcomes. Presented at AMWC 2025; Mar 27-29, 2025; Monaco
12. Fabi S, et al. Regenerative aesthetic effects of poly L-lactic acid (PLLA-SCA) treatment. Presented at AMWC 2025; Mar 27-29, 2025; Monaco
13. Nikolis A, Prygova I and Brasatar D. The potential role of biostimulators/dermal fillers to address the impact of medication driven weight loss management treatments on facial appearance. Presented at AMWC 2025; Mar 27-29, 2025; Monaco
14. Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721
15. Ablon G, et al. RelaBoNT-A treatment of glabellar lines and lateral canthal lines of different baseline severity: subgroup analyses of pooled Phase III study data. Presented at AMWC 2025; Mar 27-29, 2025; Monaco
16. Markowitz O, et al. Evaluation of synergistic effects for midface improvement when pairing Sculptra ^® (PLLA-SCA) with Alastin skincare ^® : A comparative study. Abstract presented at AMWC 2025; Mar 27-29, 2025; Monaco
17. Bromée T, et al. A new hyaluronic acid injectable, HASHA, sets new G-prime standards. Abstract presented at AMWC 2025; Mar 27-29, 2025; Monaco
18. Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–61. doi: 10.36849/JDD.8145
19. Nkolis A, et al. Hyaluronic acid fillers preserve natural movement and dynamic expression: data from three postmarketing clinical studies. Presented at AMWC 2025; Mar 27-29, 2025; Monaco
20. Percec, I et al. An Objective, Quantitative, Dynamic Assessment of Hyaluronic Acid Fillers That Adapt to Facial Movement. Plast Reconstr Surg. 2020;145:295e–305e. doi: 10.1097/PRS.0000000000006461
21. Philipp-Dormston WG, et al. Evaluating Perceived Naturalness of Facial Expression After Fillers to the Nasolabial Folds and Lower Face With Standardized Video and Photography. Dermatol Surg. 2018;44(6):826–32. doi: 10.1097/DSS.0000000000001419
22. Solish N, et al. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738–46. doi: 10.1111/jocd.12961
23. Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at: TOXINS 2021; Jan 16-17, 2021; virtual meeting
24. Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at: TOXINS 2022; July 27-30, 2022; New Orleans, LA
25. Shridharani SM, et al. Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines. ASJ. 2024; sjae131
26. Ablon G, et al. Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study. Dermatol Surg. 2024. doi: 10.1097/DSS.0000000000004470
27. Relfydess ^® . EU Summary of Product Characteristics
28. Persson C, et al. Patient and Investigator Treatment Experience with Ready-to-Use AbobotulinumtoxinA Solution Versus Powder BotulinumtoxinA for Treatment of Glabellar Lines. Abstract presented at TOXINS 2024; Jan 17-20, 2024, Berlin
29. Di Gregorio C. 25+ Years of Experience with the Restylane Portfolio of Injectable Hyaluronic Acid Fillers for Facial Aesthetic Treatment. E-poster presented at AMWC, March 27-29, 2024, Monaco
30. Nikolis A, et al. The Role of Clinical Examination in Midface Volume Correction Using Hyaluronic Acid Fillers: Should Patients Be Stratified by Skin Thickness? Aesthet Surg J Open Forum. 2020; 2(1):1–12.
31. Galderma. Data on file. Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021
32. Restylane U.S. Instructions For Use. Available online. Accessed January 2025.
33. Kablik J, et al. Comparative Physical Properties of Hyaluronic Acid Dermal Fillers: Dermatologic Surgery 35, 302–312 (2009).
34. Narins RS, et al. Persistence of nasolabial fold correction with a hyaluronic acid dermal filler with retreatment: results of an 18-month extension study. Dermatol Surg. 2011;37:644–650
35. Talarico S, et al. High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg. 2015;41:1361–1369
36. Ohrlund A, et al.. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. JDD. 2024; 23(1), pp.1332-1336
37. Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after hyaluronic acid filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-6.
38. U.S. Food and Drug Administration. Sculptra summary of safety and effectiveness data. Available online. Accessed January 2025.
39. Galderma. Data on File (MA-46589)
40. Duracinsky M, et al. Safety of poly-L-lactic acid (New-Fill ^® ) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis. 2014;14(474). doi:10.1186/1471233414474
41. Zhang S and Duan E. Fighting against Skin Aging: The Way from Bench to Bedside. Cell Transpl. 2018;27(5):729-738. doi: 10.1177/0963689717725755
42. Asius J, et al. Inventors. US patent US 7,731,758 B2.2010. Available online. Accessed January 2025
43. Morgan P, et al. Product Manufacturing Process for Poly-L-lactic acid (PLLA-SCA). Poster presented at IMCAS World Congress, January 26–28, 2023, Paris, France
44. Galderma. Data on File (MA-53568)
45. Shuster S, et al. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-43. doi: 10.1111/j.1365-2133.1975.tb05113.x
46. Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39:915–22
47. Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48: 101–108. doi: 10.1097/DSS.0000000000003239
48. Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024, October 17-20, 2024, Orlando, Florida, United States
49. Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapetite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting, October 17-20, 2024, Orlando, Florida, United States
50. Haddad S, et al. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022;61:1284–1288. doi: 10.1111/ijd.16229
51. Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51
52. Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC, March 30 - April 1, 2023, Monaco

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319676050/en/

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Sébastien Cros
Corporate Communications Director
sebastien.cros@galderma.com
+41 79 529 59 85

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

Permalink: http://www.businesswire.com/news/home/20250319676050/en